Epigenomics of leukemia: from mechanisms to therapeutic applications
- 13 October 2011
- journal article
- review article
- Published by Taylor & Francis Ltd in Epigenomics
- Vol. 3 (5), 581-609
- https://doi.org/10.2217/epi.11.73
Abstract
Leukemogenesis is a multistep process in which successive transformational events enhance the ability of a clonal population arising from hematopoietic progenitor cells to proliferate, differentiate and survive. Clinically and pathologically, leukemia is subdivided into four main categories: chronic lymphocytic leukemia, chronic myeloid leukemia, acute lymphocytic leukemia and acute myeloid leukemia. Leukemia has been previously considered only as a genetic disease. However, in recent years, significant advances have been made in the elucidation of the leukemogenesis-associated processes. Thus, we have come to understand that epigenetic alterations including DNA methylation, histone modifications and miRNA are involved in the permanent changes of gene expression controlling the leukemia phenotype. In this article, we will focus on the epigenetic defects associated with leukemia and their implications as biomarkers for diagnostic, prognostic and therapeutic applications.Funding Information
- the Recherche Cancer et Sang foundation
- the Recherches Scientifiques Luxembourg association
- the Een Haerz fir kriibskrank Kanner association
- the Action Lions Vaincre le Cancer association
- AFR fellowship from the Ministry of Research
This publication has 266 references indexed in Scilit:
- Cancer chemoprevention by dietary polyphenols: Promising role for epigeneticsBiochemical Pharmacology, 2010
- Targeting histone deacetyalses in the treatment of B- and T-cell malignanciesInvestigational New Drugs, 2010
- Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule InhibitorCell Chemical Biology, 2010
- Sp1/NFκB/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid LeukemiaCancer Cell, 2010
- Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studiesBioorganic & Medicinal Chemistry, 2009
- H3K79 Methylation Profiles Define Murine and Human MLL-AF4 LeukemiasCancer Cell, 2008
- Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene ExpressionCancer Cell, 2008
- Synergistic Effects of a Combination of Dietary Factors Sulforaphane and (−) Epigallocatechin-3-gallate in HT-29 AP-1 Human Colon Carcinoma CellsPharmaceutical Research, 2007
- Chromatin Modifications and Their FunctionCell, 2007
- The Epigenomics of CancerCell, 2007